Aequus Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Aequus Pharmaceuticals generated cash of -$2,293,985, which is less than the previous year. Cash used in financing activities reached the amount of $2,214,367 last year. Net change in cash is therefore -$79,618.
Cash Flow
| 2014 | -1.36M | 0 | 4.62M |
|---|---|---|---|
| 2015 | -3.83M | -241.46K | 1.66M |
| 2016 | -4.46M | -478.94K | 4.25M |
| 2017 | -3.81M | -48.88K | 4.55M |
| 2018 | -2.57M | -11.36K | 1.79M |
| 2019 | -1.62M | -2.67K | 1.74M |
| 2020 | -804.90K | -12.31K | 2.05M |
| 2021 | -1.17M | -507.96K | 2.39M |
| 2022 | -1.95M | 0 | -189.18K |
| 2023 | -2.29M | 0 | 2.21M |
AQS.V Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 249.81K | 2.39M | 1.71M | 484.50K | 369.89K | 1.16M | 473.24K | 1.16M | 3.57M | 311.73K |
Operating activities | ||||||||||
Net income | -2.96M | -3.21M | -1.80M | -1.04M | -3.10M | -2.80M | -3.88M | -4.81M | -5.01M | -2.41M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 138.16K | 129.83K | 128.10K | 210.96K | 309.06K | 187.79K | 187.22K | 172.40K | 86.77K | 1.49K |
Stock-based compensation expense | 50.91K | 40.94K | 215.75K | 297.64K | 201.00K | 0 | 373.31K | 675.04K | 820.91K | 495.66K |
| Deferred income tax benefit | 50.91K | 40.94K | 215.75K | 297.64K | 201.00K | 0 | 373.31K | 675.04K | 820.91K | 495.66K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 278.41K | 618.22K | -161.56K | -223.21K | 174.85K | -301.08K | -239.95K | -95.80K | -18.96K | -66.74K |
Inventories | -29.92K | 46.00K | -16.50K | -117.89K | 7.26K | -12.69K | 0 | 0 | 0 | 0 |
Accounts payable | 27.61K | -90.18K | 141.65K | -95.40K | 17.63K | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -2.29M | -1.95M | -1.17M | -804.90K | -1.62M | -2.57M | -3.81M | -4.46M | -3.83M | -1.36M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | -503.84K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -5 | 0 | -4.12K | -12.31K | -2.67K | -11.36K | -48.88K | -478.94K | -242.47K | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.01K | 0 |
Cash generated by investing activities | 0 | 0 | -507.96K | -12.31K | -2.67K | -11.36K | -48.88K | -478.94K | -241.46K | 0 |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 2.54M | 2.15M | 220 | 0 | 4.55M | 0 | 1.66M | 833.84K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 2.21M | -38K | -147.50K | -143.82K | 1.74M | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 2.21M | -189.18K | 2.39M | 2.05M | 1.74M | 1.79M | 4.55M | 4.25M | 1.66M | 4.62M |
Net Change In Cash | -79.61K | -2.14M | 717.56K | 1.23M | 114.61K | -794.62K | 691.27K | -690.57K | -2.41M | 3.26M |
Cash at end of period | 170.19K | 249.81K | 2.43M | 1.71M | 484.50K | 369.89K | 1.16M | 473.24K | 1.16M | 3.57M |